10.1158/0008-5472.CAN-06-0326
The FDA Category 2 Framework and the July 2026 PCAC Meeting In 2023, the FDA created a list of 19 peptides classified as Category 2: substances that do not currently fit the five legal compounding categories but have enough clinical interest and accumulated safety data to warrant regulatory review
These drugs fall within two categories: human GLP-1 backbone agents (that is, albiglutide, dulaglutide, liraglutide and semaglutide) and exendin-4 backbone agents (that is, exenatide, lixisenatide and tirzepatidethe latter activating both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors) 1
Intended Use: Reconstitution of lyophilized research peptides Laboratory dilutions requiring bacteriostatic conditions Multi-use sterile laboratory applications IGF-1 LR3 IGF-1 LR3 Peptide IGF-1 LR3 Peptide (Long Arg3 Insulin-Like Growth Factor-1) 1mg (Lyophilized Peptide) For Research Use Only IGF-1 LR3 is a synthetic analog of human Insulin-Like Growth Factor-1 (IGF-1), modified to extend its half-life in vitro through substitution of arginine at position 3 and removal of the first three amino acids of the native IGF-1 sequence
Dogs with full double coats tend to have body surface temperatures 4 degrees lower than those which have been trimmed or shaved because their full double coat serves to insulate the body from higher temperatures
A : Yes
